Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia.

Hypercalcaemia is an important cause of morbidity in malignant disease. We studied the efficacy and safety of intravenous ibandronate (a new, potent bisphosphonate) in a multicentre study of 147 patients with severe cancer-associated hypercalcaemia which had been resistant to treatment with rehydrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ralston, S. H., Thiébaud, D., Herrmann, Z., Steinhauer, E. U., Thürlimann, B., Walls, J., Lichinitser, M. R., Rizzoll, R., Hagberg, H., Huss, H. J., Tubiana-Hulin, M., Body, J. J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1997
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063262/
https://www.ncbi.nlm.nih.gov/pubmed/9010041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063262/
https://www.ncbi.nlm.nih.gov/pubmed/9010041

Ejemplares similares